Triazenes pp 91-96 | Cite as

The Metabolism of Antineoplastic Triazenes

  • Andreas Gescher
  • Lincoln L. H. Tsang
  • John A. Slack


Is there a future for antineoplastic triazenes in the clinic? The answer is probably no as they have been under investigation now for nearly two decades without showing satisfactory promise in the treatment of human malignancies. However, 1-aryl-3,3-dialkyltriazenes are certainly very interesting experimental agents. In particular, studies of their metabolism have furnished a marked contribution to our understanding of the link between xenobiochemistry and biological activity. These studies were mostly conducted in the 60s and 70s and they established clearly that aryldialkyltriazenes require metabolism to exert their antineoplastic and carcinogenic activity (for review see ref. 1). More recently the discovery of the remarkable antineoplastic activity in mice of mitozolomide and related imidazotetrazinones, molecules in which the triazene moiety is part of a ring structure, has led to the studies of their mode of action and their metabolism2,3. The role which metabolism plays as a determinant of biological activity is less clear for the imidazotetrazinones than in the case of the aryldimethyltriazenes. In this overview the metabolism of antineoplastic aryldimethyltriazenes and imidazotetrazinones is compared. Such a comparison might eventually contribute to the ultimate assessment of the therapeutic benefit of treatment with these agents, if indeed there is one.


Urinary Metabolite Antitumour Activity Antineoplastic Activity Hepatic Microsome Metabolic Precursor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Gescher and M.D. Threadgill, The metabolism of triazene antitumor drugs, Pharmac. Ther. 32: 191 (1987).CrossRefGoogle Scholar
  2. 2.
    C.M.T. Horgan and M.J. Tisdale, Antitumour imidazotetrazines. IV. An investigation into the mechanism of antitmumour activity of a novel and potent antitumour agent, mitozolomide. Biochem. Pharmacol. 33: 2185 (1984).PubMedCrossRefGoogle Scholar
  3. 3.
    K.R. Horspool, C.P. Quarterman, J.A. Slack, A. Gescher, M.F.G. Stevens and E. Lunt, Metabolic activation and murine pharmacokinetics of the 8-(N,N-dimethylcarboxamide) analog of the experimental antitumor drug mitozolomide (NSC353451), Cancer Res., 49: 5023 (1989).PubMedGoogle Scholar
  4. 4.
    R. Preussman and A. von Hodenberg, Mechanism of carcinogensis of 1-aryl-3,3-dialkyltriazenes. Enzymatic dealkylation by rat liver microsomal fraction in vitro, Biochem. Pharmacol. 18: 1 (1969).Google Scholar
  5. 5.
    P. Farina, A. Gescher, J.A. Hickman, J.K. Horton, M. D’Incaici, D. Ross, M.F.G. Stevens and L.C. Torti, Studies of the mode of action of antitumour triazenes and triazines. IV. The metabolism of 1-(4-acetylphenyl)-3,3-dimethgyltriazene. Biochem. Pharmacol. 31: 1887 (1982).PubMedCrossRefGoogle Scholar
  6. 6.
    P. Farina, E. Benfenati, R. Reginato, L. Torti, M. D’Incaici, M.D. Threadgill and A. Gescher, Metabolism of the anticancer agent 1-(4-acetylphenyl)-3,3-dimethyltriazene, Biomed. Mass Spectrom., 10: 485 (1983).Google Scholar
  7. 7.
    B.L. Pool, Microsomal mediated metabolism of dialkylaryltriazenes. II. Isolation and identification of metabolites of 3,3-dimethyl-1-phenyltriazene, J. Cancer Res. Clin. Oncol. 93: 221 (1979).PubMedCrossRefGoogle Scholar
  8. 8.
    A. Gescher, J.A. Hickman, R.J. Simmonds, M.F.G. Stevens and K. Vaughan, Studies of the mode of action of antitumour triazenes and triazines. II. Investigation of the selective toxicity of 1-aryl-3,3,-dimethyltriazenes. Biochem. Pharmacol. 30: 89 (1981).PubMedCrossRefGoogle Scholar
  9. 9.
    A. Gescher, J.A. Hickman, R.J. Simmonds, M.F.G. Stevens and K. Vaughan, Alpha-hydroxylated derivatives of antitumour dimethyltriazenes, Tetrahedron Lett. 50: 5041 (1978).CrossRefGoogle Scholar
  10. 10.
    G.F. Kolar and R. Carubelli, Urinary metabolites of 1-(2,4,6-tridhlorophenyl)-3,3,-dimethyltriazene with an intact diazoamino structure, Cancer Lett. 7: 209 (1979).PubMedCrossRefGoogle Scholar
  11. 11.
    G.E. Householder and T.L. Loo, Elevated urinary excretion of 4-amino imidazole-5-carboxamide in patients after iv injection of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide, Life Sci. 8: 533 (1969).CrossRefGoogle Scholar
  12. 12.
    J.L. Skibba, G. Ramirez, D.D. Beal and G.T. Bryan, Metabolism of 4(5)-(3,3-dimethyl-1-triazeno)-imidazole-5(4)-carboxamide to 4(5)-amino-imidazole-5(4)carboxamide in man, Biochem. Pharmacol. 19: 2043 (1970).PubMedCrossRefGoogle Scholar
  13. 13.
    N.S. Mizuno and E.W. Humphrey, Metabolism of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC 45388) in human and tumor tissue, Cancer Chemother. Rep. 56: 465 (1972).Google Scholar
  14. 14.
    D.L. Hill, Microsomal metabolism of triazenylimidazoles, Cancer Res. 35: 3106 (1975).PubMedGoogle Scholar
  15. 15.
    G.F. Kolar, M. Maurer and M. Wildschütte, 5-(3-Hydroxymethyl-3-methyltriazeno)imidazo-4-carboxamide, a metabolite of dacarbazine (DIC, DTIC, NSC 45388), Cancer Lett. 10: 241 (1980).CrossRefGoogle Scholar
  16. 16.
    M.F.G. Stevens, J.A. Hickman, R. Stone, N.W. Gibson, E. Lunt, C.G. Newton and G.U. Baig, Antitumor imidazotetrazines. I. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5„l-d]-l,2,3,5-tetrazine-4(3H)-one, a novel broad spectrum antitumor agent, J. Med. Chem. 27: 196 (1984).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Andreas Gescher
    • 1
  • Lincoln L. H. Tsang
    • 1
  • John A. Slack
    • 1
  1. 1.CRC Experimental Chemotherapy Research Group Pharmaceutical Sciences InstituteAston UniversityBirminghamUK

Personalised recommendations